close
MENU
Investment
6 mins to read

Aroa Biosurgery exceeds full-year revenue guidance, boosts sales team

Second south Auckland manufacturing site up and running, expected to cost $8m once finished.

Revenue is up more than expected at Auckland-based, ASX-listed soft tissue regeneration biotech Aroa Biosurgery, according to unaudited, preliminary figures released on Tuesday. 

Chief executive and founder Brian Ward said the company was on track to hit $100 million annual sales revenues in the

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Contact the Writer: nicola@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Aroa Biosurgery exceeds full-year revenue guidance, boosts sales team
Investment,
91325
true